CareDx Inc
CDNA
View Detailed Chart
14.770USD
-0.230-1.53%
Close 11/03, 16:00（ET）Quotes delayed by 15 min
786.06MMarket Cap
15.21P/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
-1.53%
5 Days
-1.34%
1 Month
-0.47%
6 Months
-1.53%
Year to Date
-31.01%
1 Year
-34.76%
View Detailed Chart
TradingKey Stock Score of CareDx Inc
Currency: USD Updated: 2025-10-31Key Insights
The company's fundamentals are relatively healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite an average stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
CareDx Inc's Score
Support & Resistance
No Data
Score Analysis
Current score
Previous score
Analyst Rating
Based on
9
analysts
Buy
Current Rating
22.500
Target Price
+50.00%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
CareDx Inc Highlights
StrengthsRisks
CareDx, Inc. is a precision medicine solutions company. The Company is focused on the discovery, development, and commercialization of clinically differentiated, diagnostic solutions for transplant patients and caregivers. The Company offers testing services, products, and patient and digital solutions along the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. Its commercially available testing services consist of AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The Company’s product portfolio includes AlloSeq Tx, QTYPE, Olerup SSP, AlloSeq HCT and AlloSeq cfDNA. It develops and provides diagnostic surveillance testing services for various transplant recipients.
Turnaround to Profit
The company's performance has turned profitable, with the latest annual net income of USD .
Overvalued
The company’s latest PE is 13.37, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 54.30M shares, decreasing 13.13% quarter-over-quarter.
Held by Catherine Wood
Star Investor Catherine Wood holds 2.10M shares of this stock.
News
More news coming soon, stay tuned...
Financial Indicators
EPS
No Data
Total revenue
No Data
CareDx Inc Info
CareDx, Inc. is a precision medicine solutions company. The Company is focused on the discovery, development, and commercialization of clinically differentiated, diagnostic solutions for transplant patients and caregivers. The Company offers testing services, products, and patient and digital solutions along the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. Its commercially available testing services consist of AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The Company’s product portfolio includes AlloSeq Tx, QTYPE, Olerup SSP, AlloSeq HCT and AlloSeq cfDNA. It develops and provides diagnostic surveillance testing services for various transplant recipients.
Ticker SymbolCDNA
CompanyCareDx Inc
CEOMr. John W. Hanna
Websitehttps://www.caredx.com/
Related Instruments
+0.95%
-1.78%
-2.37%
-1.16%
+0.44%
+0.04%
+1.56%
-1.27%
-3.65%
-1.76%
+3.54%
-0.31%
-0.87%
+0.83%
-1.58%
-2.52%
-2.09%
-1.56%
+0.58%
-0.68%Popular Symbols
